There is controversy over the role of
glycogen synthase kinase-3 (GSK-3) in
cancer progression. Recent work has implicated
GSK-3 in the regulation of
mammalian target of rapamycin (mTOR), a known player in malignant transformation. Autophagy, a self-degradation pathway, is inhibited by mTOR and is tightly associated with cell survival and
tumor growth. Here we show that
GSK-3 suppresses autophagy via mTOR complex-1 (
mTORC1) and lysosomal regulation. We show that overexpression of
GSK-3 isoforms (GSK-3α and GSK-3β) activated
mTORC1 and suppressed autophagy in MCF-7 human
breast cancer cells as indicated by reduced
beclin-1 levels and upregulation of sequestosome 1 (p62/SQSTM1). Further, overexpression of
GSK-3 increased the number of autophagosomes and inhibited autophagic flux. This activity was directly related to reduced lysosomal acidification triggered by
GSK-3 (in which GSK-3β has a stronger impact). We found that lysosomal acidification is reduced in MCF-7 cells that also exhibit increased levels of autophagosomes and p62/SQSTM1 and increased activity of
mTORC1. Subsequently, treating cells with
GSK-3 inhibitors restored lysosomal acidification, enhanced autophagic flux and inhibited
mTORC1. Furthermore,
GSK-3 inhibitors inhibited cell proliferation. We provide evidence that GSK3-mediated
mTORC1 activity and GSK-3-mediated lysosomal acidification occur via distinct pathways, yet both
mTORC1 and lysosomes control cell growth. Finally, we show that GSK-3-reduced lysosomal acidification inhibits endocytic clearance as demonstrated by reduced endocytic degradation of the
epidermal growth factor receptor. Taken together, our study places
GSK-3 as a key regulator coordinating cellular homeostasis.
GSK-3 inhibitors may be useful in targeting
mTORC1 and lysosomal acidification for
cancer therapy.